UK losing EMA relationship risks 'disruption and delay'
Warnings that patients could face delays in accessing new drugs if the UK withdraws from the European Medicines Agency (EMA) as part of the Brexit process have been issued by senior figures in British healthcare.
Sir Alasdair Breckenridge, a previous chairman of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), and Sir Kent Woods, former chairman of the EMA’s management board, were among those who expressed concerns on BBC Radio 4 on Friday morning.
"UK patients may be getting medicines 12, 18, 24 months later than in the European system"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze